HYPERRAB S/D (rabies immune globulin [human]) solution for IM injection by Grifols Grifols announced that it has a robust inventory of HyperRAB S/D (rabies immune globulin [human]) to overcome the ...
RESEARCH TRIANGLE PARK, N.C., Sept. 28, 2012 /PRNewswire/ -- Grifols, a global healthcare company that produces medicines derived from human plasma, announced today it has a robust inventory of ...
HyperRAB for intramuscular injection is now available in 3 sizes: 1mL (300 IU), 3mL (900 IU) and 5mL (1500 IU) single-dose vials. Grifols announced the launch of a new 3mL (900 IU) vial of HyperRAB® ...
HyperRAB, the only high-potency formulation at 300 IU/mL, was launched in 2018, offering twice the potency of currently available rabies immunoglobulin options and the potential for fewer injections ...
This medication is used to prevent a certain serious virus infection, rabies, in people who have been exposed to this virus under certain conditions (such as a bite wound or non-bite wound by an ...
BARCELONA, Spain, Feb. 6, 2018 /PRNewswire/ -- Grifols (MCE: GRF, MCE: GRF.P, and NASDAQ: GRFS), a leading global producer of plasma-derived medicines and provider of a variety of postexposure ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback